ADD PROGRAM SYMPOSIUM

 描述(申请人提供)：抗惊厥药物开发(ADD)计划将主办一场题为《团队科学和大数据时代的治疗发展：未来将给癫痫患者带来什么》的研讨会？本次研讨会将于2015年5月17日至2015年5月20日在德克萨斯州帕克城举行，向公众开放。尽管FDA在过去20年中批准了16种以上的抗癫痫药物，但近三分之一的癫痫患者未能完全控制癫痫发作。此外，目前还不可能预防中枢神经系统损伤后高危患者癫痫的发生。因此，有一个 迫切需要为顽固性癫痫患者和高危人群提供更有效的治疗。研讨会的目标是探索如何通过公共、联邦和私人合作伙伴关系来利用基础科学方面的创新突破来快速开发癫痫患者的新疗法。创造性的会议结构，充足的讨论时间，以及初级调查人员参与会议的各个方面，将确保新的知识、新的 合作，以及对最先进的治疗发展的新见解将是研讨会的重要成果。本申请申请资金用于部分资助受邀教员和初级调查人员的旅费，并为会议服务、印刷和视听技术提供资金。

 DESCRIPTION (provided by applicant): The Anticonvulsant Drug Development (ADD) Program will host a symposium entitled "Therapy Development in the Era of Team Science and Big Data: What Will the Future Bring to the Patient with Epilepsy"? This symposium will be held from May 17th, 2015 - May 20th, 2015 in Park City, UT and will be open to the public. Despite FDA approval of over 16 anticonvulsant drugs in the last two decades, nearly 1/3 of all patients with epilepsy fail to achieve full seizure control. In addition, it is currently not possible to prvent the development of epilepsy in patients at high risk following a CNS insult. Therefore, there is an acute need for more effective therapies for the patient with intractable epilepsy and for persons at risk. The goal of the symposium is to explore how innovative breakthroughs in basic science can be leveraged by public, federal, and private partnerships to rapidly develop new treatments for the patient with epilepsy. A creative conference structure, ample discussion time, and inclusion of junior investigators in all aspects of the meeting will insure that new knowledge, new collaborations, and new insight into state of the art therapy development will be significant outcomes of the symposium. This application requests funds to partially support travel for the invited faculty and junior investigators and to provide funds for conference services, printing, and audio-visual technologies.